Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes

Diabetes and heart failure (HF) are closely linked, with one causing a worse prognosis in the other. The majority of anti-hyperglycaemic agents primarily reduce risk of ischaemic microvascular events without targeting the mechanisms involved for diabetes cardiomyopathy and HF. Sodium–glucose cotrans...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Muhammad Shahzeb Khan, Javed Butler
Formato: article
Lenguaje:EN
Publicado: Radcliffe Medical Media 2019
Materias:
Diseases of the circulatory (Cardiovascular) system
RC666-701
Acceso en línea:https://doaj.org/article/447ccb19177f466caa5dc0828c697737
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:447ccb19177f466caa5dc0828c697737
record_format dspace
spelling oai:doaj.org-article:447ccb19177f466caa5dc0828c6977372021-12-04T16:01:59ZSodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes10.15420/cfr.2019.06.R12057-75592057-7540https://doaj.org/article/447ccb19177f466caa5dc0828c6977372019-11-01T00:00:00Zhttps://www.cfrjournal.com/articleindex/cfr.2019.06.R1https://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Diabetes and heart failure (HF) are closely linked, with one causing a worse prognosis in the other. The majority of anti-hyperglycaemic agents primarily reduce risk of ischaemic microvascular events without targeting the mechanisms involved for diabetes cardiomyopathy and HF. Sodium–glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel class of glucose-lowering agents that have consistently reduced HF hospitalisations, unlike other agents. The authors discuss the current evidence and highlight possible future directions for the role of SGLT2 inhibitors in HF prevention.Muhammad Shahzeb KhanJaved ButlerRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 5, Iss 3, Pp 169-172 (2019)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the circulatory (Cardiovascular) system
RC666-701
spellingShingle Diseases of the circulatory (Cardiovascular) system
RC666-701
Muhammad Shahzeb Khan
Javed Butler
Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
description Diabetes and heart failure (HF) are closely linked, with one causing a worse prognosis in the other. The majority of anti-hyperglycaemic agents primarily reduce risk of ischaemic microvascular events without targeting the mechanisms involved for diabetes cardiomyopathy and HF. Sodium–glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel class of glucose-lowering agents that have consistently reduced HF hospitalisations, unlike other agents. The authors discuss the current evidence and highlight possible future directions for the role of SGLT2 inhibitors in HF prevention.
format article
author Muhammad Shahzeb Khan
Javed Butler
author_facet Muhammad Shahzeb Khan
Javed Butler
author_sort Muhammad Shahzeb Khan
title Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
title_short Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
title_full Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
title_fullStr Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
title_full_unstemmed Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
title_sort sodium–glucose cotransporter-2 inhibitors and heart failure prevention in type 2 diabetes
publisher Radcliffe Medical Media
publishDate 2019
url https://doaj.org/article/447ccb19177f466caa5dc0828c697737
work_keys_str_mv AT muhammadshahzebkhan sodiumglucosecotransporter2inhibitorsandheartfailurepreventionintype2diabetes
AT javedbutler sodiumglucosecotransporter2inhibitorsandheartfailurepreventionintype2diabetes
_version_ 1718372730440515584

Ejemplares similares